Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.783480
Keywords
hepatocellular carcinoma; transarterial chemoembolization; targeted therapy; immunotherapy; comprehensive therapy
Categories
Funding
- Medicine and Health Discipline Platform Project of Zhejiang Province [2018RC019]
- Medicine and Health Science Project of Zhejiang Province [2020KY483]
- Project of Hubei Chen Xiaoping Science and Technology Development Foundation [2020CXPJJH12000008-13]
- Science Project of Beijing Medicine and Health Foundation [2020JWJKJJHKYJJ-LC19004]
Ask authors/readers for more resources
TACE combined with lenvatinib plus sintilimab is an effective and safe therapeutic regimen for unresectable hepatocellular carcinoma, showing high objective response rate, duration of response, progression-free survival, and overall survival.
ObjectiveTo assess the efficacy and safety of transarterial Chemoembolization (TACE) combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma (HCC). Patients and MethodsThe data of patients with unresectable HCC administered a combination therapy with TACE and lenvatinib plus sintilimab were retrospectively assessed. Patients received lenvatinib orally once daily 2 weeks before TACE, followed by sintilimab administration at 200 mg intravenously on day 1 of a 21-day therapeutic cycle after TACE. The primary endpoints were objective response rate (ORR) and duration of response (DOR) by the modified RECIST criteria. ResultsMedian duration of follow-up was 12.5 months (95%CI 9.1 to 14.8 months). ORR was 46.7% (28/60). Median DOR in confirmed responders was 10.0 months (95%CI 9.0-11.0 months). Median progression-free survival (PFS) was 13.3 months (95%CI 11.9-14.7 months). Median overall survival (OS) was 23.6 months (95%CI 22.2-25.0 months). ConclusionsTACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available